Elizabeth Burnside

In addition to her MD and faculty appointment in Radiology, Dr. Burnside has master’s degrees in Public Health and in Medical Informatics, and affiliate faculty positions in Biostatistics and Medical Informatics and in Industrial and Systems Engineering. Her highly multidisciplinary research involves the use of artificial intelligence methods to improve decision making in breast cancer diagnosis. These approaches integrate data from imaging, genetic factors, family history, demography, and other sources to produce more accurate, personalized diagnoses while reducing unnecessary testing and false positives. As well as other funded studies, Dr. Burnside leads an advanced project in this area at the UW-Madison Center for Predictive Computational Phenotyping, an NIH Center of Excellence for Big Data Computing in Biomedical Sciences.

Joshua Coon

Professor Joshua Coon received his Ph.D. in chemistry from the University of Florida in 2002 during which time he developed an ambient ionization technique for peptide analyses that combined laser desorption and atmospheric pressure chemical ionization. He then conducted his postdoctoral studies in the laboratory of Professor Don Hunt at the University of Virginia where he and John Syka carried out pioneering work on the development of electron transfer dissociation (ETD). This activation technique is now commonly used for the identification of labile post-translational modifications and for large-scale protein sequencing. Coon is an Associate Professor in the Departments of Chemistry and Biomolecular Chemistry at the University of Wisconsin.

His research group is primarily focused on instrumental developments in mass spectrometry and in proteomics to address fundamental questions in cell biology. With emphasis on ion chemistry and instrumentation, his group develops and applies new enabling mass spectrometry-based (MS) proteomic technologies. These cutting-edge tools allow them to examine the molecular events leading to cell differentiation of human embryonic stem cells and the combinatorial combination of histone post-translational modifications in pluripotent stem cells. His research interest also focuses on the development of ETD for intact protein sequencing, and on the use and application of algorithms enabling protein identification from product ion spectra. He holds several patents on ETD and its application to peptide sequencing.

Graham Lidgard

Graham P. Lidgard, Ph.D., was appointed Chief Science Officer of Exact Sciences in August 2009. Dr. Lidgard led the research and development organization at Gen-Probe Inc. that developed that company's Procleix blood screening products and Aptima sexually transmitted disease products. Dr. Lidgard also created and led the system development group at Gen-Probe that developed its fully automated Tigris system. Prior to joining Gen-Probe, Dr. Lidgard was co-founder and Vice President of product development of Matritech Inc., a Cambridge, Massachusetts-based developer of diagnostic products for the early detection of bladder cancer. Before he co-founded Matritech, Dr. Lidgard held senior positions at Ciba Corning Diagnostics Corp.’s worldwide diagnostics group. While at Ciba Corning, he was involved in the development of more than 70 510(k)-cleared products. He led the program for the development of the magnetic particle chemiluminescent technology that became the ACS:180 and Centaur systems. Dr. Lidgard joins Exact Sciences from Nanogen Inc., where he was Senior Vice President of research and development. Dr. Lidgard earned a Bachelor's degree with honors and a Doctorate in biological chemistry from the University of Manchester in England.

Perry Pickhardt

Dr. Perry J. Pickhardt graduated from the University of Wisconsin—Madison, his hometown school, in 1991 with a B.S. in Physics (G.P.A. 4.0, class rank 1/3,274). Beginning in 1991, Dr. Pickhardt attended the University of Michigan Medical School on the HPSP Scholarship Program and graduated as an M.D. in 1995 (Hewlett-Packard Award as a top graduate). From 1995-1999, he was a resident in diagnostic radiology at the Mallinckrodt Institute of Radiology at Washington University in St. Louis. During his training in St. Louis, Dr. Pickhardt co-edited a textbook on body CT and published a number of scientific papers. For the next four years after residency training, Dr. Pickhardt served in the U.S. Navy, spending one year as the Department Head of Radiology, U.S. Naval Hospital Guantanamo Bay, Cuba and three years as the head of GI-GU Imaging at the National Naval Medical Center (NNMC) in Bethesda, MD (twice named Teacher of the Year). He also served as an assistant professor of radiology at the Uniformed Services University of the Health Sciences in Bethesda. Among other projects at NNMC, Dr. Pickhardt organized a large multi-center screening trial evaluating CT colonography (virtual colonoscopy) and served as the primary investigator (PI). Dr. Pickhardt joined the Abdominal Imaging Section at the University of Wisconsin School of Medicine and Public Health in 2003 as an associate professor of radiology and was promoted to professor in 2009. CT colonography and colorectal cancer screening continue to be Dr. Pickhardt's primary clinical and research interests. His work in abdominal imaging has resulted in over 250 scientific publications and book chapters, as well as three textbooks. Among other honors, he has received the best paper award at the Annual Meeting for the Society of Gastrointestinal Radiology on four occasions. He currently serves as a PI on three active NIH-NCI R01 grants.

Sanford Markowitz

Dr. Sanford Markowitz is the Markowitz-Ingalls professorship of Cancer Genetics at the Case Western Reserve University School of Medicine, and is a medical oncologist and colon cancer researcher at Case Western Reserve University who is internationally recognized for his work identifying key genetics causes of colon cancer and developing molecular tests for early detection of this disease.

Dr. Markowitz serves as head of the Cancer Genetics Program at the Case Comprehensive Cancer Center and as Principal Investigator of the Case GI Cancers SPORE center, an NCI designated program of research excellence in gastrointestinal cancers. He is also an attending physician at the Seidman Cancer Center at University Hospital's Case Medical Center. Dr. Markowitz received his B.A. in chemistry and physics (summa cum laude) from Harvard University, and his M.D. and PhD. (in cell biology) from Yale University. He performed his internship and residency in internal medicine at the University of Chicago, followed by a fellowship in medical oncology at the National Cancer Institute.

Recognition of Dr. Markowitz's contributions include his election as a member of the American Society of Clinical Investigation and the Association of American Physicians and his current service on the Board of Scientific Counselors of the National Cancer Institute. Dr. Markowitz has additionally served as a member of the scientific advisory boards of: the National Colon Cancer Research Alliance founded by Ms. Katie Couric, the Dana Farber/Harvard Cancer Center, the Abramson Family Cancer Research Center of the University of Pennsylvania, and the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center.

Bert Vogelstein

Dr.  Bert Vogelstein was the first to elucidate the molecular basis of a common human cancer. His work on colorectal cancers forms the paradigm for much of modern cancer research, with profound implications for diagnostic and therapeutic strategies of the future. 

Dr, Vogelstein attended the University of Pennsylvania, where he graduated with distinction in mathematics.  He obtained his medical degree at the Johns Hopkins University School of Medicine and performed his residency in pediatrics at the Johns Hopkins Hospital.  Following his clinical training, Dr. Vogelstein completed a post-doctoral fellowship at the National Cancer Institute, focusing on the development of new approaches to study human cancers.    He is currently the Director of the Ludwig Center at the Johns Hopkins Kimmel Cancer Center and an Investigator of the Howard Hughes Medical Institute.

Dr. Vogelstein has received numerous awards recognizing his pioneering studies in   cancer genomics.  He is a member of the American Academy of Arts & Sciences, the National Academy of Sciences, the American Philosophical Society, the Institute of Medicine and the European Molecular Biology Organization.   His advisory roles have included Chairmanships of the National Research Council Committee on the Biological and Biomedical Applications of Stem Cell Research and the Board of Scientific Counselors of the National Human Genome Research Institute.  

Eric Lander

Eric S. Lander is the founding director and serves as a core member of the Broad Institute of MIT and Harvard. One of the principal leaders of the Human Genome Project, he and his colleagues have a long-standing interest in applying genomics to understand the molecular basis of human physiology and disease.

Over the past 15 years, Lander and his colleagues have created many of the key tools of human genomics and have applied these tools to pioneer new ways to understand the basis of diseases, including cancer, diabetes, and inflammatory diseases. The work includes mapping and sequencing of the human, mouse, and other genomes; understanding the functional elements encoded in genomes through comparative analysis; understanding the genetic variation in the human population and its relationship to disease susceptibility; understanding the distinctive cellular signatures of diseases and of response to drugs; understanding gene regulation; and understanding the mutations underlying cancer.

Lander was an assistant and associate professor of managerial economics at the Harvard Business School from 1981 to 1990. He has been on the MIT faculty since 1989 and the Harvard faculty since 2004. He is currently a professor of biology at MIT and professor of systems biology at Harvard Medical School. In 1990, he founded the Whitehead Institute/MIT Center for Genome Research, which was a flagship of the Human Genome Project and became part of the newly founded Broad Institute in 2003.

Lander is an elected member of the US National Academy of Sciences, the US Institute of Medicine, the American Academy of Arts and Sciences, and the Royal Swedish Academy of Sciences Class of Biosciences. He is the recipient of numerous awards, including the MacArthur Foundation Fellowship, the Gairdner International Award, the Max Delbrück Medal, the AAAS Award for Public Understanding of Science and Technology, the Dart/NYU Biotechnology Achievement Award, the Dan David Prize from Tel Aviv University, the Harvey Prize from Technion University, the Breakthrough Prize in Life Sciences, the Block Memorial Lectureship Award for Distinguished Achievement in Cancer Research, and ten honorary doctorates. He received the Albany Medical Center Prize in Medicine and Biomedical Research and the New York Academy of Medicine Medal for Distinguished Contributions in Biomedical Science. Lander has been a member of the Board of Trustees at Boston University since 2008 and, in 2009, President Barack Obama appointed him to co-chair the President’s Council of Advisors on Science and Technology.

Lander earned his B.A. in mathematics from Princeton University and his Ph.D. in mathematics from Oxford University as a Rhodes Scholar.